Table 1.
Ntg | Tta | AdvaxCpG | AV-1980R/A | |
---|---|---|---|---|
Open field (TDT) | 36.7 +/− 2.8a,b | 46.9 +/− 2.5a,b | 150.3 +/− 35.3 | 122.9 +/− 32.2 |
Ymaze entries | 32.8 +/− 1.9a,b | 34.3 +/− 1.3a,b | 57.8 +/− 9 | 59.5 +/− 7.9 |
Ymaze alternation | 60.7 +/− 3.2 | 59.9 ± 1.6 | 65.1 +/− 2.3 | 68.2 +/− 4.8 |
RAWM reversal total errors | 25 +/− 4.7 a,b,c | 40.1 +/− 2.7a,b | 92.8 +/− 13.3 | 93.4 +/− 14.6 |
RAWM post dox reversal total errors | 29.5 +/− 5.4a,b | 52.9 +/− 8.3 | 81.9 +/− 14.3 | 70.5 +/− 7.8 |
FC context | 25.6 +/− 5.4a,b | 20.7 +/− 4.7a,b | 6.6 +/− 2.3 | 2.6 +/− 1.2 |
FC cued (tone) | 42.1 +/− 7 | 26.4 +/− 5.1 | 27.7 +/− 8 | 33.6 +/− 6.7 |
Nesting behavior | 3.8 +/− 0.3a,b | 3.9 +/− 0.2a,b | 1.1 +/− 0.5 | 0.9 +/− 0.4 |
p < 0.05 when compared to AdvaxCpG adjuvant.
p < 0.05 when compared to AV-1980R/A.
p < 0.05 when compared to tTA. As expected, Tg4510 treated with AdvaxCpG adjuvant displayed hyperactivity and cognitive impairments when compared to non-transgenic or tTA littermates. Immunization with AV-1980R/A did not affect these phenotypes.